AI-Powered Tool to Transform Dermatopathology Workflow
Posted on 18 Mar 2026
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic lesions, affecting consistency and turnaround time. Laboratories are therefore seeking tools that can prioritize cases and support rigorous review as volumes rise. A new AI-driven system has now received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation to aid review of digital whole-slide images of skin lesions.
PathAssist Derm from PathAI is designed to analyze digital pathology whole slide images (WSIs) of skin lesions and assist pathologists in their review. The designation recognizes the potential of AI to support case assessment and workflow prioritization in dermatopathology. The technology applies advanced AI to digital slides to help address inter-observer variability and growing case volumes.
In dermatopathology, substantial variability has been documented for melanocytic lesions, with a large study reporting inter-observer concordance and accuracy versus a consensus reference diagnosis below 50% for diagnostically challenging classes. By supporting prioritization and structured review, the system is designed to help maintain diagnostic rigor within high-throughput workflows.
The Breakthrough Device Designation follows other recent regulatory milestones cited by the company. AISight Dx, PathAI’s digital pathology Image Management System (IMS), recently received U.S. FDA 510(k) clearance and is described as the first IMS cleared with an authorized Predetermined Change Control Plan (PCCP). AISight Dx is also CE‑IVDR–marked for primary diagnosis in the European Economic Area, the United Kingdom, and Switzerland.
In addition, AIM‑MASH AI Assist was qualified by the European Medicines Agency (EMA) and the U.S. FDA as the first AI–powered pathology Drug Development Tool (DDT) for use in metabolic dysfunction–associated steatohepatitis (MASH) clinical trials; it is not for use in diagnostic procedures.The company reports that it will continue collaborating with global regulators to advance AI-powered solutions intended to strengthen diagnostic confidence and improve patient care.
“This designation is a powerful acknowledgement of our AI capabilities and our commitment to bringing rigorously validated, clinically relevant tools to the field of digital pathology. By working closely with the FDA through the Breakthrough Devices Program, we aim to accelerate the development and review process, ensuring that this transformative technology reaches pathologists and patients as quickly as possible,” said Dr. Andy Beck, CEO at PathAI.
Related Links
PathAI
